6″-Disubstituted Amphiphilic Kanamycins

Total Page:16

File Type:pdf, Size:1020Kb

6″-Disubstituted Amphiphilic Kanamycins molecules Article Antifungal Activities of 4”,6”-Disubstituted Amphiphilic Kanamycins 1, 1, 2 2 Madher N. Alfindee y , Yagya P. Subedi y , Michelle M. Grilley , Jon Y. Takemoto and Cheng-Wei T. Chang 1,* 1 Department of Chemistry and Biochemistry, Utah State University, 0300 Old Main Hill, Logan, UT 84322-0300, USA; [email protected] (M.N.A.); [email protected] (Y.P.S.) 2 Department of Biology, Utah State University, 5305 Old Main Hill, Logan, UT 84322-5305, USA; [email protected] (M.M.G.); [email protected] (J.Y.T.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 16 April 2019; Accepted: 14 May 2019; Published: 16 May 2019 Abstract: Amphiphilic kanamycins derived from the classic antibiotic kanamycin have attracted interest due to their novel bioactivities beyond inhibition of bacteria. In this study, the recently described 4”,6”-diaryl amphiphilic kanamycins reported as inhibitors of connexin were examined for their antifungal activities. Nearly all 4”,6”-diaryl amphiphilic kanamycins tested had antifungal activities comparable to those of 4”,6”-dialkyl amphiphilic kanamycins, reported previously against several fungal strains. The minimal growth inhibitory concentrations (MICs) correlated with the degree of amphiphilicity (cLogD) of the di-substituted amphiphilic kanamycins. Using the fluorogenic dyes, SYTOXTM Green and propidium iodide, the most active compounds at the corresponding MICs or at 2 MICs caused biphasic dye fluorescence increases over time with intact cells. Further × lowering the concentrations to half MICs caused first-order dye fluorescence increases. Interestingly, 4 MIC or 8 MIC levels resulted in fluorescence suppression that did not correlate with the MIC and × × plasma membrane permeabilization. The results show that 4”,6”-diaryl amphiphilic kanamycins are antifungal and that amphiphilicity parameter cLogD is useful for the design of the most membrane-active versions. A cautionary limitation of fluorescence suppression was revealed when using fluorogenic dyes to measure cell-permeation mechanisms with these antifungals at high concentrations. Finally, 4”,6”-diaryl amphiphilic kanamycins elevate the production of cellular reactive oxygen species as other reported amphiphilic kanamycins. Keywords: amphiphilic kanamycin; Cryptococcus neoformans; antifungal; kinetic membrane permeabilization; SYTOXTM green; propidium iodide 1. Introduction Although commonly unappreciated, fungal diseases cause tremendous economic loss and health impacts globally. Annually, more than a billion people acquire fungal infections. The death rate from fungal diseases is equal to that of tuberculosis and malaria combined, with approximately 10% of those deaths due to cryptococcal meningitis [1,2]. Immunosuppressed individuals, such as those infected with HIV or undergoing treatment for cancer or organ transplants, are especially susceptible to invasive fungal infections. Current treatment options for fungal infections include polyene-based compounds (e.g., amphotericin B) [3–5], cytosine-based compounds (e.g., flucytosine) [5,6], and azole-based compounds (e.g., itraconazole and fluconazole) [5,7,8]. However, as exemplified in the recent outbreak of Candida auris [9], drug resistance is a growing problem. Further research to develop new and effective treatments for fungal diseases is urgent. Molecules 2019, 24, 1882; doi:10.3390/molecules24101882 www.mdpi.com/journal/molecules Molecules 2019, 24, 1882 2 of 12 Molecules 2019, 24, x FOR PEER REVIEW 2 of 13 Molecules 2019, 24, x FOR PEER REVIEW 2 of 13 Kanamycin belongs to a class of antibacterial compounds known as aminoglycosides that are Kanamycin belongs to a class of antibacterial compounds known as aminoglycosides that are activeKanamycin against both belongs Gram-negative to a class (G of) antibacterial and Gram-positive compounds (G+) bacteria, known albeitas aminoglycosides its clinical use is that limited are active against both Gram-negative −(G−) and Gram-positive (G+) bacteria, albeit its clinical use is dueactive to against the emergence both Gram of bacterial-negative resistance (G−) and (FigureGram-1positive)[ 10]. To(G+ overcome) bacteria, thealbeit problem its clinical of bacterial use is limited due to the emergence of bacterial resistance (Figure 1) [10]. To overcome the problem of resistance,limited due extensive to the emergence research has of beenbacterial devoted resistance to structural (Figure modifications 1) [10]. To overcome of aminoglycosides the problem that of bacterial resistance, extensive research has been devoted to structural modifications of leadbacterial to the resistance, discovery ofextensive amphiphilic research aminoglycosides has been [ 11devoted,12]. In contrast to structural to antibacterial modifications kanamycin of aminoglycosides that lead to the discovery of amphiphilic aminoglycosides [11,12]. In contrast to thataminoglycoside is inactive againsts that lead fungi, to somethe discovery of the amphiphilic of amphiphilic kanamycins aminoglycosides (AKs) were [11,12 found]. In to contrast be active to antibacterial kanamycin that is inactive against fungi, some of the amphiphilic kanamycins (AKs) againstantibacterial a wide kanamycin range of fungal that is strains inactive [13, 14against] and concomitantlyfungi, some of not the active amphiphilic against bacteria.kanamycins Two (A ofKs) the were found to be active against a wide range of fungal strains [13,14] and concomitantly not active antifungalwere found AKs to be produced active against good specific a wide antifungalrange of fungal activity: strainsFG08 [13,14, which] and contains concomitantly an octyl group not active (C8) against bacteria. Two of the antifungal AKs produced good specific antifungal activity: FG08, which chainagainst attached bacteria at. Two the 4”of positionthe antifungal of kanamycin AKs produced analog good via an specific ether linkageantifungal [15 ]activity and K20: FG08, which, which has contains an octyl group (C8) chain attached at the 4″ position of kanamycin analog via an ether ancontains octanesulfonyl an octyl groupgroup at(C8) the chain 6” position attached (Figure at the1)[ 164″]. position of kanamycin analog via an ether linkage [15] and K20, which has an octanesulfonyl group at the 6″ position (Figure 1) [16]. linkage [15] and K20, which has an octanesulfonyl group at the 6″ position (Figure 1) [16]. Figure 1. StructureStructure of aminoglycosides and selected kanamycins ( (AKs).AKs). Figure 1. Structure of aminoglycosides and selected kanamycins (AKs). AKs are known to show their antimicrobial activity by increasing the membrane permeability AKs are known to show their antimicrobial activity by increasing the membrane permeability of microorganisms [17 [17––2121]].. Fluorogenic Fluorogenic dyes, dyes, such such as as SYTOX SYTOXTM TMgreengreen and and propidium propidium iodide iodide (PI), (PI), are of microorganisms [17–21]. Fluorogenic dyes, such as SYTOXTM green and propidium iodide (PI), are commonlyare commonly employed employed for the for study the study of membrane of membrane permeabilization permeabilization (Figure (Figure 2). SYTOX2). SYTOXTM greenTM isgreen non- commonly employed for the study of membrane permeabilization (Figure 2). SYTOXTM green is non- fluorescentis non-fluorescent and cannot and cannot penetrate penetrate the plasma the plasma membrane membrane of ofintact intact organisms. organisms. However, However, in in the fluorescent and cannot penetrate the plasma membrane of intact organisms. However, in the presence ofof agentsagents thatthat compromise compromise membrane membrane integrity, integrity, SYTOX SYTOXTMTMgreen green enters enters the the cytoplasm, cytoplasm, binds binds to presence of agents that compromise membrane integrity, SYTOXTM green enters the cytoplasm, binds tonucleic nucleic acids, acids and, and emits emits fluorescence. fluorescence. Propidium Propidium iodide iodide(PI) (PI) hashas similarsimilar propertiesproperties and is widely to nucleic acids, and emits fluorescence. Propidium iodide (PI) has similar properties and is widely used for evaluating membrane permeabilization of substances in fungi and bacteria. We We recently used for evaluating membrane permeabilization of substances in fungi and bacteria. We recently reported the synthesis of 4 4”,6”-diaryl″,6″-diaryl AK AKss (compounds (compounds 11––88)) as as connexin connexin inhibitor inhibitorss [22,23 [22,23]] (Figure (Figure 3).). reported the synthesis of 4″,6″-diaryl AKs (compounds 1–8) as connexin inhibitors [22,23] (Figure 3). Since these are structurally similar to the antifungal 4”,6”-dialkyl4″,6″-dialkyl AKs (compounds 9–13), we decided decided Since these are structurally similar to the antifungal 4″,6″-dialkyl AKs (compounds 9–13), we decided to investigate their antifungal activit activitiesies and to conduct mode of action studies of both groups of to investigate their antifungal activities and to conduct mode of action studies of both groups of compounds using fluorogenicfluorogenic dyes.dyes. compounds using fluorogenic dyes. Figure 2. Structures of SYTOXTM green and propidium iodide (PI). FigureFigure 2.2. StructuresStructures ofof SYTOXSYTOXTMTM green and pro propidiumpidium iodide ( (PI).PI). Molecules 2019, 24, 1882 3 of 12 Molecules 2019, 24, x FOR PEER REVIEW 3 of 13 FigureFigure 3.3. StructureStructure ofof selectedselected AKs.AKs. 2.2. ResultsResults andand DiscussionDiscussion 2.1. Fungal Growth Inhibition by 4”,6”-Disubstituted AKs 2.1.
Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • Killing of Serratia Marcescens Biofilms with Chloramphenicol Christopher Ray, Anukul T
    Ray et al. Ann Clin Microbiol Antimicrob (2017) 16:19 DOI 10.1186/s12941-017-0192-2 Annals of Clinical Microbiology and Antimicrobials SHORT REPORT Open Access Killing of Serratia marcescens biofilms with chloramphenicol Christopher Ray, Anukul T. Shenoy, Carlos J. Orihuela and Norberto González‑Juarbe* Abstract Serratia marcescens is a Gram-negative bacterium with proven resistance to multiple antibiotics and causative of catheter-associated infections. Bacterial colonization of catheters mainly involves the formation of biofilm. The objec‑ tives of this study were to explore the susceptibility of S. marcescens biofilms to high doses of common antibiotics and non-antimicrobial agents. Biofilms formed by a clinical isolate of S. marcescens were treated with ceftriaxone, kanamy‑ cin, gentamicin, and chloramphenicol at doses corresponding to 10, 100 and 1000 times their planktonic minimum inhibitory concentration. In addition, biofilms were also treated with chemical compounds such as polysorbate-80 and ursolic acid. S. marcescens demonstrated susceptibility to ceftriaxone, kanamycin, gentamicin, and chlorampheni‑ col in its planktonic form, however, only chloramphenicol reduced both biofilm biomass and biofilm viability. Poly‑ sorbate-80 and ursolic acid had minimal to no effect on either planktonic and biofilm grown S. marcescens. Our results suggest that supratherapeutic doses of chloramphenicol can be used effectively against established S. marcescens biofilms. Keywords: Serratia marcescens, Biofilm, Antibiotics, Chloramphenicol Background addition, bacteria adhere to host’s epithelial cells through Serratia marcescens is a Gram-negative bacterium that formation of biofilm [9, 10]. The ability of S. marcescens causes infections in plants, insects, and animals, includ- to form biofilms contributes to its pathogenicity [1, 11].
    [Show full text]
  • (ESVAC) Web-Based Sales and Animal Population
    16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1.
    [Show full text]
  • Evaluation of Antibiotic Resistance Pattern in Clinical Isolates of Staphylococcus Aureus
    Evaluation of antibiotic resistance pattern in clinical isolates of Staphylococcus aureus Erum Hanif* and Shafaq Aiyaz Hassan Department of Biotechnology, University of Karachi, Karachi, Pakistan Abstract: Staphylococcus aureus is a common skin colonizer as well as opportunistic pathogen causing serious diseases including bacteremia, endocarditis and a number of different infections. It has a unique ability to swiftly respond and develop resistance for every other antibiotic introduced against it. The prevalence of antibiotic resistant strains of S. aureus is increasing on an alarming rate, which not only restrains the treatment options but the economic deprivation sustained due to infections of this superbug are incomputable. In our study, antimicrobial resistance patterns for 13 different antibiotics were evaluated in non-duplicate isolates of MSSA and MRSA isolated from different clinical samples (i.e. urine, pus, HVS, blood, tissue, wound and ear swabs). Most cultures were identified as multi-drug resistant (MDR). The highest resistance was recorded against ampicillin and erythromycin (88% each), while resistances against oxacillin, fosfomycin, cefoxitin and ciprofloxacin were also worrisome. No strain was sensitive to all antibiotics. Resistance levels of MSSA against ampicillin, erythromycin, fosfomycin and fusidic acid were also high. Least level of resistance was observed in case of vancomycin. Only 12% isolates were resistant to vancomycin, among which 24 were MRSA and 6 was MSSA. Keywords: Staphylococcus aureus, MDR, MRSA, MSSA,
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • MINIREVIEW Aminoglycoside Research 1975-1985: Prospects for Development of Improved Agents KENNETH E
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1986, p. 543-548 Vol. 29, No. 4 0066-4804/86/040543-06$02.00/0 Copyright © 1986, American Society for Microbiology MINIREVIEW Aminoglycoside Research 1975-1985: Prospects for Development of Improved Agents KENNETH E. PRICE Industrial Consultant, Microbiology and Antibiotic Chemistry, 201 Barnstable Ct., Camillus, New York 13031 INTRODUCTION Mueller-Hinton medium, were used to estimate relative potencies. The MIC50 of the gentamicin C complex (genta- Following the synthesis of amikacin and the discovery of micin C) was arbitrarily assigned a value of 1.0, and potency its unique properties in 1972 (16, 36), there were high values of all other AGs were calculated on the basis of their expectations that even more potent and broader-spectrum activity relative to this standard. aminoglycosides (AGs) could be synthesized or identified in Another important measure of the relative effectiveness of soil-organism screens. Consequently, existing research pro- marketed AGs is the degree of their susceptibility to the grams were scaled up, and some new ones were initiated. modifying action of microbially produced enzymes. The Such efforts were surely justified, because AGs had proven comparative response of each of the AGs to the 10 most fully over the preceding decade to be the principal weapon in the characterized enzymes was considered in this evaluation. armamentarium available for the treatment of seriously ill Enzymes included the AG phosphotransferases APH (3')-I, patients. This key role evolved because, as a class, AGs APH (3')-II, and APH (2"); the adenylyltransferases AAD possess many of the properties considered by infectious (4') and AAD (2"); and the acetyltransferases AAC (2'), disease specialists to be inherently associated with an ideal AAC (6'), AAC (3)-I, AAC (3)-II, and AAC (3)-III.
    [Show full text]
  • An Efficient and Highly Reproducible Approach for the Selection of Upland Transgenic Cotton Produced by Pollen Tube Pathway Method
    AJCS 7(11):1714-1722 (2013) ISSN:1835-2707 An efficient and highly reproducible approach for the selection of upland transgenic cotton produced by pollen tube pathway method Noreen Bibi1,2, Kai Fan1, Shuna Yuan1, Mi Ni1, Imrul Mosaddek Ahmed1, Waqas Malik1, 3, Xuede Wang1* 1Department of Crop Sciences, College of Agriculture and Biotechnology, Zijingang Campus, Zhejiang University, Yu Hang Tang Road 866, Hangzhou 310058, PR China 2Plant Breeding Genetics Division, Nuclear Institute for Agriculture and Biology (NIAB), Jhang Road Faisalabad, Pakistan 3Department of Plant Breeding and Genetics, Bahauddin Zakariya University, Multan, Pakistan Corresponding author: [email protected] Abstract Pollen tube pathway mediated transformation is most favorable genotype-independent approach and has been widely used for the production of transgenic crops all over the world. We used this technique to transform Zheda B, an upland cotton, by two different vectors i.e. pCAMBIA1301 with hpt gene for hygromycin resistance and pCAMBIA 2301 having nptII gene for kanamycin resistance. A preliminary experiment was conducted to find out suitable concentration of kanamycin (100-600 mg/L) and hygromycin (25-150 mg/L) for the screening of transgenic plants. Results revealed that both antibiotics caused a significant reduction in seed germination, seedling survival, plant height, root length, fresh and dry weight of root and shoot as compared to their respective controls. Furthermore, 500 mg/L kanamycin and 75 mg/L hygromycin were established as effective dozes to eliminate 80- 85% of non-transgenic seedlings during seedling stage. The outcomes of the preliminary experiment were applied to select transgenic plants from T1 population, which were later confirmed by PCR and GUS staining.
    [Show full text]
  • Ionic Dressing for Topical Administration of Drugs to Wounds and Burns
    Europaisches Patentamt 0 338 173 © European Patent Office © Publication number: A1 Office europeen des brevets © EUROPEAN PATENT APPLICATION © Application number: 88402820.0 © Int. CI* A61L 15/03 © Date of filing: 09.11.88 © Priority: 22.04.88 CA 564950 © Applicant: RICOH KYOSAN, INC. Yaesu-Mitsui Bldg. 7-2 Yaesu 2-Chome © Date of publication of application: Chuo-ku 25.10.89 Bulletin 89/43 Tokyo(JP) © Designated Contracting States: © Inyentor: Yamazaki, Hiroshi AT BE CH DE ES FR GB GR IT LI LU NL SE 22 Alderbrook Drive Nepean Ontario, K2H 5W5(CA) Inventor: Miyazaki, Masao 6-4-1 1 1 ,1-Chome§Hikarigaoka Nerima-ku Tokyo(JP) © Representative: Brycman, Jean et al CABINET ORES 6, Avenue de Messine F-75008 Paris(FR) Ionic dressing for topical administration of drugs to wounds and burns. © Novel wound dressings are provided herein. The wound dressing includes a substrate and a physiologically- or biologically- active agent adsorbed therein. The substrate is chemically modified to have ionic-adsorbing sites thereon. The agent is in its ionic form. Upon contact with body exudate from wounds to which such wound dressing is applied, the physiologically- or biologically- active agent is released in a controlled manner by ion exchange with the ions in the body exudate in proportion to the amount of exudate. CO r> oo CO CO Qm 1X1 Xerox Copy Centre EP 0 338 173 A1 IONIC DRESSING FOR TOPICAL ADMINISTRATION OF DRUGS TO WOUNDS AND BURNS This invention relates to ionic forms of dressings to which a variety of ionic, physiologically- and/or biologically-active materials can be adsorbed so that a controlled release of that material into body exudates of wounds can take place.
    [Show full text]
  • ESVAC 8Th Report. Sales of Veterinary Antimicrobial Agents in 30
    Sales of veterinary antimicrobial agents in 30 European countries in 2016 Trends from 2010 to 2016 Eighth ESVAC report An agency of the European Union Mission statement The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role • involves representatives of patients, healthcare professionals and other stakeholders in its work, to facilitate dialogue on The European Medicines Agency (hereinafter ‘the Agency’ issues of common interest; or EMA) is the European Union (EU) body responsible for coordinating the existing scientific resources put at its disposal • publishes impartial and comprehensible information about by Member States for the evaluation, supervision and medicines and their use; pharmacovigilance of medicinal products. • develops best practice for medicines evaluation and The Agency provides the Member States and the institutions supervision in Europe, and contributes alongside the Member of the EU and the European Economic Area (EEA) countries States and the EC to the harmonisation of regulatory with the best-possible scientific advice on any questions standards at the international level. relating to the evaluation of the quality, safety and efficacy of medicinal products for human or veterinary use referred to it in accordance with the provisions of EU legislation Guiding principles relating to medicinal products. • We are strongly committed to public and animal health. The founding legislation of the Agency is Regulation (EC) No • We make independent recommendations based on scien- 726/2004 of the European Parliament and the Council of 31 tific evidence, using state-of-the-art knowledge and March 2004 laying down Community procedures for the expertise in our field.
    [Show full text]
  • (As Amikacin Sulfate) 250 Mg / Ml Amikacin
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrAMIKACIN SULFATE INJECTION USP Amikacin (as Amikacin Sulfate) 250 mg / mL Antibiotic Marcan Pharmaceuticals Inc. Date of Preparation 2 Gurdwara Road, Suite #112 September 20, 2018 Ottawa, ON - K2E 1A2 Control # 198586 PrAmikacin Sulfate Injection USP Amikacin (as Amikacin Sulfate) 250 mg / mL amikacin THERAPEUTIC CLASSIFICATION Antibiotic ACTION AND CLINICAL PHARMACOLOGY Amikacin is a semi-synthetic aminoglycoside antibiotic which exhibits activity primarily against gram-negative organisms, including Pseudomonas. It is a bactericidal antibiotic affecting bacterial growth by specific inhibition of protein synthesis in susceptible bacteria. Pharmacokinetics: Amikacin is readily available and rapidly absorbed via the IV and IM routes of administration. The mean serum half-life is 2.2 hours with a mean renal clearance rate of 1.24 mL/kg/min. No accumulation is associated with dosing at 12 hour intervals in individuals with a normal renal function. In 36 neonates, after IM or IV administration of 7.5 mg/kg every 12 hours, the mean serum half-life is 5.4±2.0 hours and the mean peak serum level is 17.7±5.4 mcg/mL. No accumulation has been observed for a dosing period of 10 to 14 days. After an IM dose of 7.5 mg/kg to 8 neonates, the mean peak serum level was reached at 32 minutes. Amikacin is not metabolized; small amounts (1 to 2% of the dose) are excreted in the bile, while the remainder 98 to 99% is excreted in the urine via glomerular filtration. The mean human serum protein binding is 11% over a concentration range of 5 to 50 mcg/mL of serum.
    [Show full text]
  • PRODUCT INFORMATION Kanamycin a Item No
    PRODUCT INFORMATION Kanamycin A Item No. 16140 CAS Registry No.: 59-01-8 Formal Name: O-3-amino-3-deoxy-α-D- OH OH glucopyranosyl-(1→6)-O- OH OH H O O [6-amino-6-deoxy-α-D- NH2 glucopyranosyl-(1→4)]-2-deoxy- O O D-streptamine OH H2N NH2 OH MF: C18H36N4O11 FW: 484.5 Purity: ≥95% H2N OH Supplied as: A crystalline solid Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Kanamycin A is supplied as a crystalline solid. Kanamycin A is sparingly soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. For biological experiments, we suggest that organic solvent-free aqueous solutions of kanamycin A be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of kanamycin A in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Kanamycin A is a broad spectrum antibiotic isolated from a soil streptomyces (S. kanamyceticus). This aminoglycoside alters translation by prokaryotic ribosomes, resulting in bacterial cell death.1 In molecular biology, kanamycin A is used as a selective agent to isolate transformants that are expressing a kanamycin resistance gene, usually neomycin phosphotransferase (NptII/neo). This mode of selection is most commonly used in plant and mammalian biology. Reference 1. Misumi, M. and Tanaka, N. Mechanism of inhibition of translocation by kanamycin and viomycin: A comparative study with fusidic acid. Biochem. Biophys. Res. Commun. 92(2), 647-654 (1980).
    [Show full text]
  • Comparison of Gentamicin and Kanamycin Alone and in Combination with Ampicillin in Experimental Escherichia Coli Bacteremia and Meningitis
    003 1-3998/85/19 11-1 152$02.00/0 PEDIATRIC RESEARCH Vol. 19, No. 1 1, 1985 Copyright O 1985 International Pediatric Research Foundation, Inc. Printed in U.S. A. Comparison of Gentamicin and Kanamycin Alone and in Combination with Ampicillin in Experimental Escherichia coli Bacteremia and Meningitis KWANG SIK KIM Departmc~ntof Pediatrics, UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509 ABSTRACT. The conventional antimicrobial therapy of The most distressing aspect of neonatal gram-negative infec- gram-negative infection in the newborn is the combination tion is lack of significant improvements in the mortality and of ampicillin and an aminoglycoside, usually gentamicin or morbidity attributable to recent advances in antimicrobial kanamycin. Although gentamicin and kanamycin have been chemotherapy. A recent multicenter study of neonatal gram- used interchangeably, efficacies of the two drugs have not negative meningitis clearly showed that moxalactam, a potent been carefully compared. In addition, the contribution of new 0-lactam antibiotic, was not more effective than a combi- ampicillin to the outcome of neonatal gram-negative men- nation of ampicillin and an aminoglycoside (1). Thus, the amino- ingitis is controversial. We evaluated the activity of gen- glycosides still remain the mainstay in the treatment of neonatal tamicin and kanamycin alone and in combinations with gram-negative infection. However, whether all aminoglycoside ampicillin in vitro and in vivo against a K, Escherichia coli antibiotics will have similar activities in vivo against susceptible strain. In vitro, the E. coli strain was relatively sensitive gram-negative bacilli is not known. Moreover, the contribution to ampicillin, gentamicin, and kanamycin, with the minimal of ampicillin to the final outcome of neonatal gram-negative inhibitory and minimal bactericidal concentrations of 2 and meningitis is controversial.
    [Show full text]